View Past PerformanceKaneka バランスシートの健全性財務の健全性 基準チェック /56Kanekaの総株主資本は¥504.8B 、総負債は¥211.7Bで、負債比率は41.9%となります。総資産と総負債はそれぞれ¥953.5Bと¥448.7Bです。 Kanekaの EBIT は¥32.1Bで、利息カバレッジ比率17.9です。現金および短期投資は¥47.0Bです。主要情報41.93%負債資本比率JP¥211.68b負債インタレスト・カバレッジ・レシオ17.9x現金JP¥47.04bエクイティJP¥504.78b負債合計JP¥448.71b総資産JP¥953.48b財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 14+ 1 more updateKaneka Corporation, Annual General Meeting, Jun 26, 2026Kaneka Corporation, Annual General Meeting, Jun 26, 2026.お知らせ • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026お知らせ • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026お知らせ • Nov 12+ 1 more updateKaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.お知らせ • Nov 10Kaneka Expands Global Reach with i-ED COIL Launch in EuropeKaneka Corporation has begun sales of its i-ED COIL, a brain aneurysm embolization coil in Europe as of October. The product obtained EC certification under an EU Medical Device Regulation in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. Looking ahead, company aim to strengthen the global reach of products such as i-ED COIL and achieve sales of JPY 300 billion by 2030 in the Health Care Solution Unit including these medical businesses.お知らせ • Sep 01Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025お知らせ • Jun 13Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025お知らせ • May 16Kaneka Corporation (TSE:4118) announces an Equity Buyback for 3,000,000 shares, representing 4.77% for ¥12,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.77% of the outstanding shares for ¥12,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies in response to changes in the business environment. The program will run until March 29, 2026. As of April 30, 2025, the company had 62,934,292 shares outstanding and 3,065,708 shares in treasury.お知らせ • May 14Kaneka Corporation, Annual General Meeting, Jun 27, 2025Kaneka Corporation, Annual General Meeting, Jun 27, 2025.お知らせ • Mar 21Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025お知らせ • Jan 09Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd.Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus device for aneurysm treatment currently under development. We aim to achieve sales of over ¥20 billion by 2030. Kaneka Corporation (TSE:4118) completed the acquisition of 96.80% stake in EndoStream Medical Ltd on December 23, 2024.お知らせ • Dec 21Kaneka Corporation to Report Q3, 2025 Results on Feb 13, 2025Kaneka Corporation announced that they will report Q3, 2025 results on Feb 13, 2025お知らせ • Sep 18Kaneka Corporation to Report Q2, 2025 Results on Nov 12, 2024Kaneka Corporation announced that they will report Q2, 2025 results on Nov 12, 2024お知らせ • Jun 18Kaneka Corporation to Report Q1, 2025 Results on Aug 08, 2024Kaneka Corporation announced that they will report Q1, 2025 results on Aug 08, 2024お知らせ • May 16Kaneka Corporation, Annual General Meeting, Jun 27, 2024Kaneka Corporation, Annual General Meeting, Jun 27, 2024.お知らせ • Mar 13Kaneka Corporation to Report Fiscal Year 2024 Results on May 14, 2024Kaneka Corporation announced that they will report fiscal year 2024 results on May 14, 2024お知らせ • Nov 30Kaneka Corporation to Report Q3, 2024 Results on Feb 08, 2024Kaneka Corporation announced that they will report Q3, 2024 results on Feb 08, 2024お知らせ • Sep 13Kaneka Corporation to Report Q2, 2024 Results on Nov 09, 2023Kaneka Corporation announced that they will report Q2, 2024 results on Nov 09, 2023お知らせ • Jun 15Kaneka Corporation to Report Q1, 2024 Results on Aug 09, 2023Kaneka Corporation announced that they will report Q1, 2024 results on Aug 09, 2023お知らせ • May 17Kaneka Corporation, Annual General Meeting, Jun 29, 2023Kaneka Corporation, Annual General Meeting, Jun 29, 2023.お知らせ • Dec 17Kaneka Corporation to Report Q3, 2023 Results on Feb 08, 2023Kaneka Corporation announced that they will report Q3, 2023 results on Feb 08, 2023財務状況分析短期負債: KANK.Fの 短期資産 ( ¥466.6B ) が 短期負債 ( ¥319.0B ) を超えています。長期負債: KANK.Fの短期資産 ( ¥466.6B ) が 長期負債 ( ¥129.7B ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: KANK.Fの 純負債対資本比率 ( 32.6% ) は 満足できる 水準であると考えられます。負債の削減: KANK.Fの負債対資本比率は、過去 5 年間で35.3%から41.9%に増加しました。債務返済能力: KANK.Fの負債は 営業キャッシュフロー によって 十分にカバー されています ( 20.2% )。インタレストカバレッジ: KANK.Fの負債に対する 利息支払い は EBIT ( 17.9 x coverage) によって 十分にカバーされています。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YMaterials 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/19 15:42終値2026/01/20 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kaneka Corporation 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Kyoji ChibaBofA Global ResearchTakao KanaiCitigroup IncKeita IkedaDaiwa Securities Co. Ltd.13 その他のアナリストを表示
お知らせ • May 14+ 1 more updateKaneka Corporation, Annual General Meeting, Jun 26, 2026Kaneka Corporation, Annual General Meeting, Jun 26, 2026.
お知らせ • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026
お知らせ • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026
お知らせ • Nov 12+ 1 more updateKaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.
お知らせ • Nov 10Kaneka Expands Global Reach with i-ED COIL Launch in EuropeKaneka Corporation has begun sales of its i-ED COIL, a brain aneurysm embolization coil in Europe as of October. The product obtained EC certification under an EU Medical Device Regulation in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. Looking ahead, company aim to strengthen the global reach of products such as i-ED COIL and achieve sales of JPY 300 billion by 2030 in the Health Care Solution Unit including these medical businesses.
お知らせ • Sep 01Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
お知らせ • Jun 13Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025
お知らせ • May 16Kaneka Corporation (TSE:4118) announces an Equity Buyback for 3,000,000 shares, representing 4.77% for ¥12,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.77% of the outstanding shares for ¥12,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies in response to changes in the business environment. The program will run until March 29, 2026. As of April 30, 2025, the company had 62,934,292 shares outstanding and 3,065,708 shares in treasury.
お知らせ • May 14Kaneka Corporation, Annual General Meeting, Jun 27, 2025Kaneka Corporation, Annual General Meeting, Jun 27, 2025.
お知らせ • Mar 21Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025
お知らせ • Jan 09Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd.Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus device for aneurysm treatment currently under development. We aim to achieve sales of over ¥20 billion by 2030. Kaneka Corporation (TSE:4118) completed the acquisition of 96.80% stake in EndoStream Medical Ltd on December 23, 2024.
お知らせ • Dec 21Kaneka Corporation to Report Q3, 2025 Results on Feb 13, 2025Kaneka Corporation announced that they will report Q3, 2025 results on Feb 13, 2025
お知らせ • Sep 18Kaneka Corporation to Report Q2, 2025 Results on Nov 12, 2024Kaneka Corporation announced that they will report Q2, 2025 results on Nov 12, 2024
お知らせ • Jun 18Kaneka Corporation to Report Q1, 2025 Results on Aug 08, 2024Kaneka Corporation announced that they will report Q1, 2025 results on Aug 08, 2024
お知らせ • May 16Kaneka Corporation, Annual General Meeting, Jun 27, 2024Kaneka Corporation, Annual General Meeting, Jun 27, 2024.
お知らせ • Mar 13Kaneka Corporation to Report Fiscal Year 2024 Results on May 14, 2024Kaneka Corporation announced that they will report fiscal year 2024 results on May 14, 2024
お知らせ • Nov 30Kaneka Corporation to Report Q3, 2024 Results on Feb 08, 2024Kaneka Corporation announced that they will report Q3, 2024 results on Feb 08, 2024
お知らせ • Sep 13Kaneka Corporation to Report Q2, 2024 Results on Nov 09, 2023Kaneka Corporation announced that they will report Q2, 2024 results on Nov 09, 2023
お知らせ • Jun 15Kaneka Corporation to Report Q1, 2024 Results on Aug 09, 2023Kaneka Corporation announced that they will report Q1, 2024 results on Aug 09, 2023
お知らせ • May 17Kaneka Corporation, Annual General Meeting, Jun 29, 2023Kaneka Corporation, Annual General Meeting, Jun 29, 2023.
お知らせ • Dec 17Kaneka Corporation to Report Q3, 2023 Results on Feb 08, 2023Kaneka Corporation announced that they will report Q3, 2023 results on Feb 08, 2023